First Patient Enrolled in Stage 2 of Pivotal Study of SetPoint Medical’s Pioneering Technology for the Trea...Read Press Release from
October 10, 2022
Valencia, CA – April 30, 2019 – SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, announced today that Murthy Simhambhatla, Ph.D., President and Chief Executive Officer, is scheduled to present at the Bank of America Merrill Lynch Health Care Conference, being held May 14-17, 2019 in Las Vegas, Nevada.
Event: Bank of America Merrill Lynch Health Care Conference 2019
Location: Encore Hotel
Date: Thursday, May 16, 2019
Presentation Time: 9:35am PT
Investors attending the conference who would like to schedule a one-on-one meeting with SetPoint management may do so by contacting their Bank of America Merrill Lynch representative, or Emma Poalillo of The Ruth Group at [email protected].
About SetPoint Medical
SetPoint Medical is a privately held clinical-stage bioelectronic medicine company dedicated to treating patients with chronic autoimmune diseases. SetPoint Medical’s bioelectronic medicine platform is intended to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy. The company is developing a novel bioelectronic medicine platform that stimulates the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect. Current investors in the company include New Enterprise Associates (NEA), Morgenthaler Ventures, Topspin Partners, SightLine Partners, GlaxoSmithKline’s Action Potential Venture Capital and Boston Scientific as well as an additional undisclosed strategic investor (leading medical device company). For more information, visit www.setpointmedical.com.
Investor Relation Contacts:
Lee Roth / Emma Poalillo
The Ruth Group